Catalyst Pharmaceuticals (CPRX) Tops Q1 EPS by 34c, Beats on Revenue; Offers FY25 Revenue Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. SPY
9. XYZ
10. FISV

Go back to Catalyst Pharmaceuticals (CPRX) Tops Q1 EPS by 34c, Beats on Revenue; Offers FY25 Revenue Guidance

Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update

May 7, 2025 4:14 PM EDT

Catalyst Enters 2025 With Strong Momentum; Reiterates Confidence in Full-Year Outlook

Delivers Record Q1 2025 Total Revenues of $141.4 Million, a 43.6% YoY Increase

FIRDAPSE® and AGAMREE® Drive Sustained Organic Growth, Underscoring Execution Strength

Reaffirms Full-Year 2025 Total Revenue Guidance Provided Earlier This Year of Between $545 Million and $565 Million

Strengthens Balance Sheet with Cash and Cash Equivalents of $580.7 Million and No Debt as of March 31, 2025

Conference Call and Webcast to be Held on May 8, 2025, at 8:30 AM ET

CORAL GABLES,... More